HHS Proposes Loosening Testosterone Therapy Warning Requirements

Written by The Life Science Feed Editorial Team · Published 19 June 2026 · Edited by William Lopes

> The Department of Health and Human Services (HHS) has put forward proposed modifications to the prescribing information for testosterone therapy, specifically concerning warnings related to cardiovascular events. This move could lead to a re-evaluation of the risk-benefit profile by clinicians when considering testosterone replacement for patients with hypogonadism.

KEY TAKEAWAYS

- The Pivot: HHS proposes to reduce the prominence of cardiovascular risk warnings on testosterone product labels.
- The Data: The proposal reflects a re-evaluation of the strength of evidence linking testosterone therapy to increased cardiovascular risk.
- The Action: Clinicians should monitor for final guidance and be prepared to adjust patient counselling regarding testosterone therapy risks.

Testosterone therapy is indicated for men with hypogonadism, a condition characterised by deficient testosterone production and associated symptoms. Historically, concerns regarding the cardiovascular safety of exogenous testosterone have led to prominent warnings on product labels, advising caution in patients with pre-existing cardiovascular disease or those at elevated risk. These warnings have influenced prescribing patterns and patient selection, prompting clinicians to weigh the potential benefits of symptom amelioration against the perceived cardiovascular hazards.

Hypogonadism affects a significant proportion of the male population, with prevalence increasing with age. Symptoms can include decreased libido, erectile dysfunction, fatigue, depressed mood, reduced muscle mass and strength, and increased visceral fat. Diagnosis typically involves measuring morning total testosterone levels, often requiring confirmation with a second measurement. Treatment aims to restore testosterone levels to the physiological range, thereby alleviating symptoms and improving quality of life. The decision to initiate therapy involves a careful consideration of the patient's symptoms, testosterone levels, and overall health status, including comorbidities.

Proposed Changes and Rationale

The HHS proposal aims to revise the current warnings, which have been in place following regulatory actions in 2015 that mandated a class-wide warning about potential increased risk of heart attack and stroke. The proposed changes suggest that the evidence base supporting a causal link between testosterone therapy and major adverse cardiovascular events (MACE) is less definitive than previously interpreted. This re-evaluation considers data from various observational

studies and randomised controlled trials, which have yielded conflicting or inconclusive results regarding cardiovascular safety. For instance, some studies have indicated a potential increase in cardiovascular events in specific patient populations, while others have not demonstrated a statistically significant elevation in risk. The proposed modifications seek to align the product labelling with the current understanding of the evidence, potentially reducing the emphasis on a direct causal relationship and instead focusing on the need for individualised patient assessment and monitoring.

The methodology underpinning the re-evaluation involves a comprehensive review of published literature, including meta-analyses and systematic reviews that synthesize data from multiple studies. This process critically appraises the design, execution, and statistical power of the included studies, paying particular attention to patient selection criteria, duration of follow-up, and definitions of cardiovascular endpoints. Discrepancies in study findings often arise from heterogeneity in patient populations, such as differences in baseline cardiovascular risk, age, and the presence of other comorbidities like diabetes or obesity. Furthermore, variations in testosterone formulations, dosing regimens, and methods of testosterone level monitoring can contribute to differing outcomes across studies.

The current labelling advises clinicians to consider the potential for increased cardiovascular risk, particularly in older men or those with pre-existing cardiovascular conditions. The proposed changes may shift this language to reflect a more nuanced understanding, possibly moving from a prominent 'black box' warning to a less emphatic statement within the 'Warnings and Precautions' section. This adjustment could imply that while cardiovascular events remain a consideration, the evidence does not uniformly support a heightened risk across all patient populations receiving testosterone therapy. The rationale behind this proposal is to ensure that product information accurately reflects the totality of scientific evidence, avoiding undue alarm while still informing prescribers of potential concerns.

Implications for Clinical Practice

Should these proposed changes be finalised, they could have several implications for clinical practice. Prescribing clinicians may find themselves with greater flexibility in initiating and continuing testosterone therapy, particularly in patients who might have previously been deemed too high-risk due to cardiovascular concerns. The revised warnings could lead to a re-evaluation of existing guidelines and clinical algorithms for managing hypogonadism. It is imperative that clinicians continue to conduct thorough cardiovascular risk assessments for all patients considering testosterone therapy, irrespective of the specific wording on product labels. Monitoring for adverse events, including cardiovascular ones, will remain a critical component of patient care. The changes do not negate the importance of shared decision-making, where patients are fully informed of all known and potential risks and benefits associated with testosterone treatment.

The potential mechanisms by which testosterone might influence cardiovascular health are complex and not fully elucidated. Testosterone can affect lipid profiles, blood pressure, insulin sensitivity, and endothelial function. While some studies suggest a beneficial effect on certain cardiovascular risk factors, others raise concerns about potential pro-thrombotic effects or adverse impacts on myocardial oxygen demand in vulnerable individuals. The limitations of current evidence often include insufficient sample sizes in specific high-risk subgroups, lack of long-term follow-up data in some trials, and the challenge of isolating the effect of testosterone from other confounding factors in observational studies. Therefore, ongoing vigilance and further research are essential to refine our understanding of testosterone's long-term cardiovascular safety profile.

CLINICAL IMPLICATIONS

The HHS's proposed softening of testosterone therapy warnings represents a significant shift in regulatory posture, one that will likely be met with both relief and scrutiny. For clinicians, this could mean a loosening of the perceived shackles that have constrained testosterone prescribing since the 2015 warnings. The initial regulatory response to observational data, which suggested a link between testosterone and cardiovascular events, led to a cautious, sometimes overly conservative, approach. If the final guidance reduces the prominence of these warnings, it may empower prescribers to focus more on the symptomatic relief for patients with confirmed hypogonadism, rather than being disproportionately swayed by an unproven cardiovascular risk.

However, this does not absolve clinicians of their responsibility to conduct rigorous patient selection and monitoring. The absence of a definitive causal link does not equate to the absence of risk. Patients, particularly those with pre-existing cardiovascular disease or multiple risk factors, will still require careful evaluation.

The pharmaceutical industry, which has seen a plateau in testosterone prescriptions since the heightened warnings, may view this as an opportunity for market expansion. Companies like AbbVie, with its product AndroGel, and Endo International, with Aveed, could see renewed interest in their offerings. It will be crucial for these manufacturers to support ongoing research into the long-term cardiovascular safety of testosterone, rather than simply leveraging a less stringent label for increased sales.

Ultimately, the onus remains on the medical community to interpret the evolving evidence responsibly. While the HHS proposal reflects a more nuanced understanding of the data, it is not a carte blanche for indiscriminate prescribing. The goal should always be to treat symptomatic hypogonadism effectively and safely, with a clear understanding of the individual patient's risk profile. This regulatory adjustment should prompt a renewed focus on robust, adequately powered clinical trials to definitively characterise the cardiovascular safety profile of testosterone therapy, rather than relying on shifting interpretations of observational data.

EDITORIAL & AI STANDARDS

AI tools are used to structure and summarise evidence from peer-reviewed primary sources. Articles that carry a signed Editor's take have been read in full by William Lopes. The others are not individually read by an editor, so check the cited source before relying on a figure.

REFERENCES

1. 1. Jaiswal V, et al. Association between testosterone replacement therapy and cardiovascular outcomes: A meta-analysis of 30 randomized controlled trials. Prog Cardiovasc Dis. 2024;85:45-53. doi:10.1016/j.pcad.2024.04.001
2. 2. Braga MAP, et al. Long-Term Cardiovascular Safety of Testosterone-Replacement Therapy in Middle-Aged and Older Men: A Meta-analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs. 2025;25(6):767-777. doi:10.1007/s40256-025-00737-w
3. 3. Sood A, et al. Cardiovascular Outcomes of Hypogonadal Men Receiving Testosterone Replacement Therapy: A Meta-analysis of Randomized Controlled Trials. Endocr Pract. 2024;30(1):2-10. doi:10.1016/j.eprac.2023.09.012
4. 4. Miner M, et al. The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clin Endocrinol (Oxf). 2018;89(1):3-10. doi:10.1111/cen.13589
5. 5. Desroches B, et al. Testosterone therapy in the new era of Food and Drug Administration oversight. Transl Androl Urol. 2016;5(2):207-12. doi:10.21037/tau.2016.03.13

6. 6. Ahmed T, et al. Is Testosterone Replacement Safe in Men with Cardiovascular Disease?. Cureus. 2020;12(3):e7324. doi:10.7759/cureus.7324

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com